A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, disease, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2026-08-28		NCT07075185

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Kelonia Therapeutics, Inc.	1

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope	Duarte	United States	238
Emory University Hospital	Atlanta	United States	131
John Theurer Cancer Center, Hackensack University Medical Center	Hackensack	United States	3
Massachusetts General Hospital	Boston	United States	1015
Moffitt Cancer Center	Tampa	United States	523
Peter MacCallum Cancer Centre	Melbourne	Australia	149
Providence Portland Medical Center	Portland	United States	324
Stanford University	Palo Alto	United States	161
The Alfred Paula Fox Melanoma and Cancer Centre	Melbourne	Australia	1
The Royal Prince Alfred	Camperdown	Australia	1
UCSF	San Francisco	United States	27